NovaBridge Biosciences Cash Provided by (Used in) Financing Activities, Discontinued Operations
NovaBridge Biosciences (NBP) reported Cash Provided by (Used in) Financing Activities, Discontinued Operations of $0 for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations · last filed 2026-04-07
- NovaBridge Biosciences cash provided by (used in) financing activities, discontinued operations for the quarter ending 2025-12-31 was $0.00.
- NovaBridge Biosciences cash provided by (used in) financing activities, discontinued operations for the quarter ending 2025-09-30 was $0.00.
- NovaBridge Biosciences cash provided by (used in) financing activities, discontinued operations for the quarter ending 2024-12-31 was $0.00.
- NovaBridge Biosciences cash provided by (used in) financing activities, discontinued operations for the quarter ending 2024-09-30 was $0.00.
| Period end | Cash Provided by (Used in) Financing Activities, Discontinued Operations 3 month | Cash Provided by (Used in) Financing Activities, Discontinued Operations 6 month | Cash Provided by (Used in) Financing Activities, Discontinued Operations 9 month | Cash Provided by (Used in) Financing Activities, Discontinued Operations 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 20-F 12 month − 6-K 9 month · filed 2026-04-07 | $0.00 derived: sum of 2 quarters · filed 2026-04-07 | $0.00 20-F · filed 2026-04-07 | |
| 2025-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2025-12-18 | $0.00 6-K · filed 2025-12-18 | ||
| 2025-06-30 | $0.00 6-K · filed 2025-10-06 | |||
| 2024-12-31 | $0.00 derived: 20-F 12 month − 6-K 9 month · filed 2026-04-07 | $0.00 derived: sum of 2 quarters · filed 2026-04-07 | -$4.17M 20-F · filed 2026-04-07 | |
| 2024-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2025-12-18 | -$4.17M 6-K · filed 2025-12-18 | ||
| 2024-06-30 | -$4.17M 6-K · filed 2025-10-06 | |||
| 2023-12-31 | $9.91M 20-F · filed 2026-04-07 | |||
| 2022-12-31 | $2.81M 20-F · filed 2025-04-03 |